Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 0.55 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | ASPH | Q12797 | 1/20 | 0.42 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774128 | 0.94 | EGLN1 (0.62) | EGLN1 | |
| SCHEMBL1772698 | 0.93 | EGLN1 (0.50) | EGLN1 | |
| SCHEMBL1773687 | 0.93 | EGLN1 (0.50) | EGLN1 | |
| SCHEMBL1773592 | 0.93 | EGLN1 (0.60) | EGLN1THRATHRB | |
| SCHEMBL1774106 | 0.93 | EGLN1 (0.55) | EGLN1THRATHRB | |
| SCHEMBL12602056 | 0.93 | EGLN1 (0.50) | EGLN1THRATHRB | |
| SCHEMBL1773196 | 0.92 | EGLN1 (0.49) | EGLN1 | |
| SCHEMBL1773123 | 0.92 | EGLN1 (0.52) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL1773456 | 0.92 | EGLN1 (0.51) | EGLN1 | |
| SCHEMBL1772871 | 0.91 | EGLN1 (0.61) | EGLN1BBOX1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | claimed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | EPOR, CBR1, CBR3 | EGLN1 16/4885BBOX1 1783/4885FTO 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.